Suppr超能文献

乳糜泻

Celiac Disease

作者信息

Taylor Annette K, Lebwohl Benjamin, Snyder Cara L, Green Peter HR

机构信息

Associate VP, Strategic Director, Pharmacogenomics;, Scientific Director, Molecular Genetics, Labcorp, Englewood, Colorado

Professor of Medicine and Epidemiology, Celiac Disease Center, Columbia University, New York, New York

Abstract

CLINICAL CHARACTERISTICS

Celiac disease is a common systemic autoimmune disease that can develop in genetically susceptible individuals as a response to dietary gluten. Celiac disease can be associated with gastrointestinal findings (e.g., diarrhea, malabsorption, abdominal pain and distention, bloating, vomiting, and weight loss) and/or highly variable non-gastrointestinal findings (dermatitis herpetiformis, iron deficiency anemia, osteoporosis/osteopenia, other nutrient deficiencies, migraines, chronic fatigue, epilepsy, depression, attention-deficit/hyperactivity disorder, joint pain/inflammation, infertility and/or recurrent fetal loss, delayed puberty, growth deficiency, dental enamel hypoplasia, abnormal liver function, autoimmune disorders, and increased risk of cancer). Classical celiac disease, characterized by prominent gastrointestinal symptoms, is less common than non-classical celiac disease, characterized by mild or absent gastrointestinal symptoms. Some individuals with celiac disease have no symptoms despite the presence of immune reactivity to gluten; these individuals are referred to as having silent celiac disease.

DIAGNOSIS/TESTING: The diagnosis of celiac disease is established in an individual with positive celiac serologic testing results while on a gluten-containing diet (tissue transglutaminase immunoglobulin [Ig] A, anti-deamidated gliadin-related peptide IgA and/or IgG, or endomysial antibody IgA) and characteristic histologic findings on small bowel biopsy. Human leukocyte antigen (HLA) molecular genetic testing to detect celiac-associated and alleles is not necessary for initial diagnostic testing, but it is useful for diagnostic evaluation when serology or small biopsy results are inconclusive or discrepant. A negative result for celiac HLA genetic testing rules out celiac disease and a positive result identifies predisposition to celiac disease. Celiac HLA genetic testing is important for individuals who started a gluten-free diet before diagnostic evaluation.

MANAGEMENT

Lifelong adherence to a strict gluten-free diet (avoidance of wheat, rye, and barley). Nutrition assessment for those with persistent gastrointestinal manifestations despite removal of gluten from the diet; consider corticosteroids and immunosuppressants for refractory celiac disease; assess for malignancy in those with persistent poor weight gain and/or growth efficiency; consider dapsone for dermatitis herpetiformis; standard treatment for anemia if not responsive to gluten-free diet; standard treatment of osteoporosis; treatment of nutritional deficiencies (iron, zinc, calcium, fat-soluble vitamins, folic acid). Standard treatments for peripheral neuropathy, ataxia, seizures, migraines, poor school performance, psychiatric manifestations, joint pain and inflammation, fertility issues, pubertal delay, dental enamel hypoplasia, autoimmune disease, and cancer; evaluation for alternative causes of abnormal liver function if unresolved with gluten-free diet. For symptomatic individuals responsive to a gluten-free diet, abnormal celiac disease serologies should be followed to normalization; physical examination and assessment of growth, nutritional status, and non-gastrointestinal disease manifestations annually or as needed; measurement of hepatic profile and thyroid-stimulating hormone annually. Follow-up biopsy of intestinal villi can be considered for monitoring two years after diagnosis among individuals with a clinical and serologic response. Normalization of the intestinal biopsy is considered the aim of treatment with the diet. Dietary gluten. Celiac HLA genetic testing of first-degree relatives of a proband (including young children) for celiac-associated and alleles and determination of HLA-DQ status can be used to identify those who are susceptible to developing celiac disease and who would benefit from serologic testing to screen for celiac disease or silent celiac disease. Early diagnosis of celiac disease and treatment with a gluten-free diet can prevent secondary complications.

GENETIC COUNSELING

Celiac disease is a complex multifactorial disorder. The risk to family members of a proband with celiac disease depends on their HLA genetic risk (i.e., their HLA-DQ status, the strongest determinant of celiac disease susceptibility), less well-recognized variants in non-HLA genes, exposure to dietary gluten, and the involvement of additional environmental influences. Empiric risk for celiac disease can be estimated based on HLA-DQ status and familial relationship to the proband.

摘要

临床特征

乳糜泻是一种全身性自身免疫性疾病,可伴有胃肠道表现(腹泻、吸收不良、腹痛腹胀、肠胃气胀、呕吐和体重减轻)和/或高度可变的非胃肠道表现(疱疹样皮炎、慢性疲劳、关节疼痛/炎症、缺铁性贫血、偏头痛、抑郁、注意力缺陷障碍、癫痫、骨质疏松症/骨质减少、不孕和/或反复流产、维生素缺乏、身材矮小、发育不良、青春期延迟、牙釉质缺陷和自身免疫性疾病)。典型乳糜泻以轻度至重度胃肠道症状为特征,不如以无胃肠道症状为特征的非典型乳糜泻常见。

诊断/检测:乳糜泻的诊断基于以下个体:在含麸质饮食期间进行的乳糜泻血清学检测呈阳性(组织转谷氨酰胺酶IgA、抗脱酰胺麦醇溶蛋白相关肽IgA和IgG、肌内膜抗体IgA)、小肠活检的特征性组织学发现,以及通过对[具体基因]进行分子基因检测确定的人类白细胞抗原(HLA)单倍型DQ2或DQ8。

管理

终身严格坚持无麸质饮食(避免食用小麦、黑麦和大麦);治疗营养缺乏(铁、锌、钙、脂溶性维生素、叶酸);骨质疏松症的标准治疗。对于对无麸质饮食无反应的个体,评估难治性乳糜泻、溃疡性肠炎、T细胞淋巴瘤和其他胃肠道癌症。对于对无麸质饮食有反应的有症状个体,应跟踪异常血清学指标直至恢复正常,定期进行体格检查并评估生长、营养状况和非胃肠道疾病表现。膳食麸质。对先证者的一级亲属(包括幼儿)进行分子基因检测,以监测那些已知携带乳糜泻易感等位基因的个体是否有乳糜泻的早期迹象,以便在疾病过程早期开始无麸质饮食。

遗传咨询

乳糜泻是一种多因素疾病,由已知与乳糜泻易感性相关的[具体基因]等位基因变异、非HLA基因中较不为人知的变异、麦醇溶蛋白(麸质的一个亚成分)和其他环境因素相互作用引起。有一些针对高危亲属的经验性风险数据。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验